European Journal of Cancer
Volume 39, Issue 3 , Pages 353-357 , February 2003

The activity of raltitrexed (Tomudex®) in malignant pleural mesothelioma: an EORTC phase II study (08992)

  • P. Baas

      Affiliations

    • The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    • Corresponding Author InformationCorresponding author
    • ,
  • A. Ardizzoni

      Affiliations

    • Instituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
    • ,
  • F. Grossi

      Affiliations

    • Universita degli Studi di Udine, Udine, Italy
    • ,
  • K. Nackaerts

      Affiliations

    • University Hospital Gasthuisberg, Belgium
    • ,
  • G. Numico

      Affiliations

    • Ospedale Santa Croce, Cuneo, Italy
    • ,
  • E. Van Marck

      Affiliations

    • University of Antwerp, Dept of Pathology, Antwerp, Belgium
    • ,
  • M. van de Vijver

      Affiliations

    • The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    • ,
  • F. Monetti

      Affiliations

    • Instituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
    • ,
  • M.J.A. Smid-Geirnaerdt

      Affiliations

    • Stichting Oosterschelde Ziekenhuizen, Goes, The Netherlands
    • ,
  • N. van Zandwijk

      Affiliations

    • The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    • ,
  • C. Debruyne

      Affiliations

    • The EORTC Data Center, Brussels, Belgium
    • ,
  • C. Legrand

      Affiliations

    • The EORTC Data Center, Brussels, Belgium
    • ,
  • G. Giaccone

      Affiliations

    • Academisch Ziekenhuis der Vrije Universiteit, Amsterdam, The Netherlands
    • ,
  • on behalf of the EORTC Lung Cancer Group

Received 15 October 2002 ,Accepted 16 October 2002.

References 

  1. Van Meerbeeck J, Debruyne C, Van Zandwijk N, et al.  Paclitaxel for malignant mesothelioma (a phase II study of the EORTC LCCG). Brit. J. Cancer. 1996;74:961–963
  2. Baas P, Van Meerbeeck J, Groen H, et al.  Caelyx in malignant mesothelioma (a phase II EORTC study). Ann. Oncol. 2000;11:697–700
  3. Van Meerbeeck JP, Baas P, Debruyne C, et al.  A phase II EORTC study of temozolamide in patients with malignant pleural mesothelioma. Eur. J. Cancer. 2002;38:779–783
  4. Baas P. Chemotherapy for malignant mesothelioma (from doxorubicin to vinorelbine). Semin. Oncol. 2002;29:62–69
  5. Ong ST, Vogelzang NJ. Chemotherapy in malignant mesothelioma. A review. J. Clin. Oncol. 1996;14:1007–1017
  6. Halme M, Knuuttila A, Vehmas T, et al.  High dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma. Br. J. Cancer. 1999;80:1781–1785
  7. Solheim OP, Saeter G, Finnanger AM, Stenwig AE. High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study. Br. J. Cancer. 1992;65:956–960
  8. Van Cutsem E, Cunningham D, Maroun J, et al.  Raltitrexed (current clinical status and future directions). Ann. Oncol. 2002;13:513–522
  9. Cunningham D, Zalcberg J, Maroun J, et al.  Efficacy, tolerability and management of raltitrexed (Tomudex®) monotherapy in patients with advanced colorectal cancer, a review of phase II/III trials. Eur. J. Cancer. 2002;38:478–486
  10. Scheithauer W, Kornek GV, Raderer M, et al.  Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first line treatment in advanced colorectal cancer. J. Clin. Oncol. 2002;20:165–172
  11. Fizazi K, Caliandro R, Soulie P, et al.  Combination raltitrexed (Tomudex®)–oxaliplatin (a step forward in the struggle against mesothelioma? The Institute Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma). Eur. J. Cancer. 2000;36:1514–1521
  12. Therasse P, Arbuck SG, Eisenhauer E, et al.  New guidelines to evaluate the response to treatment in solid tumors. JNCI. 2000;92:3; 205–216
  13. International Mesothelioma Interest Group . A new staging system for malignant mesothelioma. Chest. 1995;108:1122–1126
  14. Fleming TR. One sample multiple testing procedure for phase II clinical trials. Biometrics. 1982;38:143–151
  15. Hughes A, Calvert P, Azzabi A, et al.  Phase I clinical and pharmacokinetic study of pemetrexed in patients with malignant pleural mesothelioma. J. Clin. Onc. 2002;20:3533–3544
  16. Shin DM, Scagliotti G, Kindler H, et al. A phase II trial of pemetrexed in malignant pleural mesothelioma (MPM) patients: clinical outcome, role of vitamin suppletion, respiratory symptoms and lung function. Proc ASCO 2002, 21, (abstr 1175).
  17. Vogelzang NJ, Rusthoven J, Paoletti P, et al. Phase III single blinded study of pemetrexed and cisplatin versus cisplatin alone in chemonaive patients with malignant pleural mesothelioma. Proc ASCO 2002, 2a (abstr 5).
  18. EJC. Potential treatment for pleural mesothelioma. Eur J Cancer 2002, 38, 1556.

PII: S0959-8049(02)00668-8

European Journal of Cancer
Volume 39, Issue 3 , Pages 353-357 , February 2003

Article Tools